Krsnaa Diagnostics (KRSNAA) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Jul, 2026Executive summary
Achieved strong growth in Q2 and H1 FY2025, driven by operational efficiency, increased patient footfalls, new project wins, and strategic investments in high-growth healthcare sectors such as oncology and cardiac care.
Expanded geographic footprint to 150+ districts across 18 states/UTs, with major contracts in Jharkhand, Assam, Maharashtra, Madhya Pradesh, and Odisha, including 45 new radiology centers, one pathology lab, and 731 collection centers.
Entered strategic partnerships with United Imaging and Medikabazaar to enhance diagnostic capabilities and expand into Tier 2 and Tier 3 cities, with plans for 30+ imaging and pathology centers and favorable financing terms.
Strategic investment in Apulki Healthcare for exclusive oncology and cardiac diagnostics partnership, securing a 30-year contract and long-term revenue visibility.
Focused on asset-light, technology-enabled expansion and a patient-centric retail strategy to diversify revenue streams.
Financial highlights
Q2 FY2025 consolidated revenue reached ₹1,863.40 million, up 20% year-on-year; H1 FY2025 consolidated revenue at ₹3,565.72 million, up 21% year-on-year.
Q2 EBITDA was ₹509 million, up 58% year-on-year; H1 EBITDA at ₹951 million, up 48% year-on-year.
Q2 PAT stood at ₹195.96 million, up 87% year-on-year; H1 PAT at ₹375.17 million, up 49% year-on-year.
Maintained net debt-free status with cash and equivalents of ₹112.79 million as of September 2024.
Receivables at ₹243 crores, with ₹125 crores from two states; company expects receivable days to normalize to 90 by year-end.
Outlook and guidance
Confident in achieving 25% revenue growth for FY2025, with sustainable EBITDA margins above previous guidance.
Guidance for CapEx remains at ₹1,700 million for FY2025.
Margins expected to remain stable, supported by operational efficiencies and cost-saving initiatives.
Focus on tapping underpenetrated diagnostic markets via new PPP tenders and expanding retail presence.
Plans to leverage digital marketing, process automation, and cost control for sustained profitability.
Latest events from Krsnaa Diagnostics
- Q1 FY27 revenue up 22% YoY, retail surges 64%, margins compress, dividend and warrants approved.KRSNAA
Q1 26/27 - Revenue, profit, and margins rose in FY 2026, with retail and PPP expansion and dividend declared.KRSNAA
Q4 25/26 - 9M FY26 revenue up 9%, Q3 retail revenue surges nearly 8x, and network expansion accelerates.KRSNAA
Q3 25/26 - Q2 FY26 delivered record PAT, strong revenue and EBITDA growth, with retail and PPP expansion fueling momentum.KRSNAA
Q2 25/26 - Q1 FY26 delivered double-digit growth, margin expansion, retail surge, and a major PPP contract win.KRSNAA
Q1 2026 - Q1 FY25 delivered 22% revenue and profit growth, margin expansion, and a final dividend.KRSNAA
Q1 2025 - Q3 FY25 delivered 10% revenue and 50% profit growth, with strong outlook as new centers expand.KRSNAA
Q3 24/25 - Strong FY25 growth in revenue and profit, retail expansion, and dividend proposed amid tax appeals.KRSNAA
Q4 24/25